Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Top Cited Papers
- 16 November 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (20) , 2085-2098
- https://doi.org/10.1056/nejmoa065485
Abstract
Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin deficiency. Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined.Keywords
This publication has 28 references indexed in Scilit:
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Target Hemoglobin Level for EPO Therapy in CKDAmerican Journal of Kidney Diseases, 2006
- Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKDAmerican Journal of Kidney Diseases, 2005
- Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trialKidney International, 2004
- Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysisKidney International, 2004
- Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4)Journal of the American Society of Nephrology, 2004
- Development of the Kidney Disease Quality of Life (KDQOLTM) InstrumentQuality of Life Research, 1994
- Estimation and sample size considerations for clustered binary responsesStatistics in Medicine, 1994
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- On the receiving end—II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapyEuropean Journal of Cancer and Clinical Oncology, 1983